News articles about Dimension Therapeutics (NASDAQ:DMTX) have trended somewhat negative this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dimension Therapeutics earned a media sentiment score of -0.03 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.1727461163495 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Dimension Therapeutics, Inc. (DMTX) Expected to Post Earnings of -$0.49 Per Share (americanbankingnews.com)
- Analyzing Dimension Therapeutics (NASDAQ:DMTX) & vTv Therapeutics (VTVT) (americanbankingnews.com)
- Dimension Therapeutics, Inc. (DMTX) Short Interest Update (americanbankingnews.com)
- Actinobac Biomed Receives Up To $4.4M Investment (finsmes.com)
Dimension Therapeutics (DMTX) traded up 3.70% during midday trading on Thursday, reaching $1.40. 17,811 shares of the company’s stock traded hands. The firm’s 50-day moving average is $1.30 and its 200-day moving average is $1.94. The company’s market capitalization is $35.06 million. Dimension Therapeutics has a 1-year low of $1.05 and a 1-year high of $9.98.
Dimension Therapeutics (NASDAQ:DMTX) last announced its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.02. The company had revenue of $3.62 million for the quarter. Dimension Therapeutics had a negative return on equity of 80.04% and a negative net margin of 412.27%. Analysts forecast that Dimension Therapeutics will post ($2.17) earnings per share for the current year.
A number of equities analysts recently commented on DMTX shares. Canaccord Genuity dropped their price target on shares of Dimension Therapeutics from $20.00 to $12.00 and set a “buy” rating for the company in a research note on Wednesday, June 28th. Zacks Investment Research cut shares of Dimension Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, July 10th. Citigroup Inc. cut shares of Dimension Therapeutics from a “buy” rating to a “neutral” rating and set a $1.50 price target for the company. in a research note on Friday, May 12th. Finally, Cantor Fitzgerald set a $3.00 price target on shares of Dimension Therapeutics and gave the stock a “hold” rating in a research note on Saturday, June 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $5.88.
ILLEGAL ACTIVITY NOTICE: “Dimension Therapeutics (NASDAQ:DMTX) Given News Sentiment Score of -0.03” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/07/20/dimension-therapeutics-nasdaqdmtx-given-news-sentiment-score-of-0-03.html.
Dimension Therapeutics Company Profile
Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).
Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.